Liposome-encapsulated doxorubicin (Doxil) and doxorubicin in the treatment of vaccine-associated sarcoma in cats.
The purpose of this randomized, multicenter study was to evaluate the toxicity and efficacy of liposome-encapsulated doxorubicin (LED) and doxorubicin (DOX) in the treatment of feline vaccine-associated sarcoma (VAS). Cats were divided according to their disease status into a microscopic arm (no evidence of gross disease) and a macroscopic arm (evidence of gross disease). Each arm was randomized to receive either LED (1-1.5 mg/kg i.v. q3 weeks) or DOX (1 mg/kg i.v. q3 weeks). Thirty-three cats were entered in the macroscopic arm of the study with an overall response rate of 39% (5 complete response and 8 partial response) and a median time to progression of 84 days. Response rates were not different between LED and DOX. Seventy-five cats were entered into the microscopic arm. When compared to a similar historical control population treated with surgery alone, the cats receiving chemotherapy had a prolonged median disease-free interval (388 days versus 93 days). No difference in efficacy was detected between LED and DOX. LED at 1.5 mg/kg induced delayed nephrotoxicosis in 23%, necessitating a decrease in the recommended dosage to 1 mg/kg, and cutaneous toxicosis in 21.7% of treated cats. This study showed that both DOX and LED are efficacious in the treatment of VAS and should be considered in the treatment of this tumor.
Poirier
Valerie J
VJ
Department of Medical Sciences, University of Wisconsin-Madison, School of Veterinary Medicine, Madison, WI 53706, USA.
Thamm
Douglas H
DH
Kurzman
Ilene D
ID
Jeglum
K Ann
KA
Chun
Ruthanne
R
Obradovich
Joyce E
JE
O'Brien
Maura
M
Fred
Rogers M
RM
Phillips
Brenda S
BS
Vail
David M
DM
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D002371:Cat Diseases / Q000188:drug therapy* / Q000209:etiology; D002415:Cats; D004317:Doxorubicin / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D008081:Liposomes; D008297:Male; D012509:Sarcoma / Q000188:drug therapy* / Q000209:etiology / Q000662:veterinary*; D012983:Soft Tissue Neoplasms / Q000188:drug therapy* / Q000209:etiology / Q000662:veterinary*; D016896:Treatment Outcome; D014611:Vaccination / Q000009:adverse effects* / Q000662:veterinary*
D000970:Antineoplastic Agents; D008081:Liposomes; D004317:Doxorubicin